How did FOLD's revenue and expenses trend in Q4 2024?

In Q4 2024, Amicus Therapeutics (FOLD) experienced a decline in advertising and marketing expenses by 5.21%, while R&D expenses remained stable at $30.19 million. The revenue by segment also showed a decrease, with a reported revenue of $528.3 million for the business/product segment, $378.59 million for an unspecified segment, and $125.25 million for another business/product segment. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |FOLD|FOLD.O|Amicus Therapeutics|20240101-2024|Product|5.28295E8|185| |FOLD|FOLD.O|Amicus Therapeutics|20240101-2024|Product|3.78589E8|185| |FOLD|FOLD.O|Amicus Therapeutics|20240101-2024|Product|2.37072E8|185| |FOLD|FOLD.O|Amicus Therapeutics|20240101-2024|Product|1.10403E8|185| |FOLD|FOLD.O|Amicus Therapeutics|20240101-2024|Product|1.10403E8|185| |code|Ticker|Name|Date|R&D Expenses|market_code| |---|---|---|---|---|---| |FOLD|FOLD.O|Amicus Therapeutics|2024 Q1|2.8329E7|185| |FOLD|FOLD.O|Amicus Therapeutics|2024 Q2|2.4683E7|185| |FOLD|FOLD.O|Amicus Therapeutics|2024 Q3|2.616E7|185| |FOLD|FOLD.O|Amicus Therapeutics|2024 Q4|3.019E7|185|